121 related articles for article (PubMed ID: 26564251)
1. Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women.
Leal AD; Thompson CA; Wang AH; Vierkant RA; Habermann TM; Ross JA; Mesa RA; Virnig BA; Cerhan JR
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):151-7. PubMed ID: 26564251
[TBL] [Abstract][Full Text] [Related]
2. Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort.
Leal AD; Thompson CA; Wang AH; Vierkant RA; Habermann TM; Ross JA; Mesa RA; Virnig BA; Cerhan JR
Int J Cancer; 2014 Apr; 134(7):1741-50. PubMed ID: 24114627
[TBL] [Abstract][Full Text] [Related]
3. Lifestyle factors and risk of myeloproliferative neoplasms in the NIH-AARP diet and health study.
Podoltsev NA; Wang X; Wang R; Hofmann JN; Liao LM; Zeidan AM; Mesa R; Ma X
Int J Cancer; 2020 Aug; 147(4):948-957. PubMed ID: 31904114
[TBL] [Abstract][Full Text] [Related]
4. Diet and Risk of Myeloproliferative Neoplasms in Older Individuals from the NIH-AARP Cohort.
Podoltsev NA; Wang X; Wang R; Hofmann JN; Liao LM; Zeidan AM; Mesa RA; Ma X
Cancer Epidemiol Biomarkers Prev; 2020 Nov; 29(11):2343-2350. PubMed ID: 32868318
[TBL] [Abstract][Full Text] [Related]
5. A Pooled Analysis of Reproductive Factors, Exogenous Hormone Use, and Risk of Multiple Myeloma among Women in the International Multiple Myeloma Consortium.
Costas L; Lambert BH; Birmann BM; Moysich KB; De Roos AJ; Hofmann JN; Baris D; Wang SS; Camp NJ; Tricot G; Atanackovic D; Brennan P; Cocco P; Nieters A; Becker N; Maynadié M; Foretová L; Boffetta P; Staines A; Brown EE; de Sanjosé S
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):217-21. PubMed ID: 26464426
[TBL] [Abstract][Full Text] [Related]
6. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
7. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
Mesa R; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Boyle J; Mascarenhas JO
BMC Cancer; 2016 Feb; 16():167. PubMed ID: 26922064
[TBL] [Abstract][Full Text] [Related]
8. Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN).
Price GL; Davis KL; Karve S; Pohl G; Walgren RA
PLoS One; 2014; 9(3):e90299. PubMed ID: 24618579
[TBL] [Abstract][Full Text] [Related]
9. Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.
Kaifie A; Isfort S; Gattermann N; Hollburg W; Klausmann M; Wolf D; Maintz C; Hänel M; Goekkurt E; Göthert JR; Platzbecker U; Geer T; Parmentier S; Jost E; Serve H; Ehninger G; Berdel WE; Brümmendorf TH; Koschmieder S;
Ann Hematol; 2016 Sep; 95(9):1399-410. PubMed ID: 27334946
[TBL] [Abstract][Full Text] [Related]
10. Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway.
Roaldsnes C; Holst R; Frederiksen H; Ghanima W
Eur J Haematol; 2017 Jan; 98(1):85-93. PubMed ID: 27500783
[TBL] [Abstract][Full Text] [Related]
11. Breast Tumor Prognostic Characteristics and Biennial vs Annual Mammography, Age, and Menopausal Status.
Miglioretti DL; Zhu W; Kerlikowske K; Sprague BL; Onega T; Buist DS; Henderson LM; Smith RA;
JAMA Oncol; 2015 Nov; 1(8):1069-77. PubMed ID: 26501844
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms.
Potthoff A; Attia D; Pischke S; Mederacke I; Beutel G; Rifai K; Deterding K; Heiringhoff K; Klempnauer J; Strassburg CP; Manns MP; Bahr MJ
Liver Int; 2015 Aug; 35(8):2042-9. PubMed ID: 25736096
[TBL] [Abstract][Full Text] [Related]
13. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
14. Clinical risk factors of thrombosis in patients with Ph-negative myeloproliferative neoplasms, who had experienced radiation exposure due to the Chornobyl accident.
Mishcheniuk OY; Klymenko SV
Probl Radiac Med Radiobiol; 2013; (18):232-9. PubMed ID: 25191727
[TBL] [Abstract][Full Text] [Related]
15. Dkk3 levels in patients with myeloproliferative neoplasms.
Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
[TBL] [Abstract][Full Text] [Related]
16. Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study.
Martinelli I; De Stefano V; Carobbio A; Randi ML; Santarossa C; Rambaldi A; Finazzi MC; Cervantes F; Arellano-Rodrigo E; Rupoli S; Canafoglia L; Tieghi A; Facchini L; Betti S; Vannucchi AM; Pieri L; Cacciola R; Cacciola E; Cortelezzi A; Iurlo A; Pogliani EM; Elli EM; Spadea A; Barbui T
Am J Hematol; 2014 Nov; 89(11):E200-5. PubMed ID: 25042466
[TBL] [Abstract][Full Text] [Related]
17. Menstrual and reproductive factors, exogenous hormone use, and risk of thyroid carcinoma in postmenopausal women.
Kabat GC; Kim MY; Wactawski-Wende J; Lane D; Wassertheil-Smoller S; Rohan TE
Cancer Causes Control; 2012 Dec; 23(12):2031-40. PubMed ID: 23090034
[TBL] [Abstract][Full Text] [Related]
18. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
19. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.
Tworoger SS; Missmer SA; Barbieri RL; Willett WC; Colditz GA; Hankinson SE
J Natl Cancer Inst; 2005 Apr; 97(8):595-602. PubMed ID: 15840882
[TBL] [Abstract][Full Text] [Related]
20. Hormone Use, Reproductive History, and Risk of Lung Cancer: The Women's Health Initiative Studies.
Schwartz AG; Ray RM; Cote ML; Abrams J; Sokol RJ; Hendrix SL; Chen C; Chlebowski RT; Hubbell FA; Kooperberg C; Manson JE; O'Sullivan MJ; Rohan T; Stefanick ML; Wactawski-Wende J; Wakelee H; Simon MS
J Thorac Oncol; 2015 Jul; 10(7):1004-13. PubMed ID: 25852020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
